Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

By M. Elman, L. P. Aiello, Roy W. Beck, N. Bressler, S. Bressler, A. R. Edwards, F. L. Ferris, S. Friedman, A. Glassman, K. Miller and 3 more. Ophthalmology (Rochester, Minn.), 2010

1,445 citations recorded by the source corpus.

Purpose To evaluate the safety and efficacy of intravitreal ranibizumab combined with prompt or deferred laser or intravitreal triamcinolone combined with prompt laser compared to laser alone for diabetic macular edema (DME).

Subfields: Ophthalmology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/77c4fd600b4bab80d7dbe4ef95fea872e1c103c8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ophthalmology

1. Tien Yin Wong
2. T. Kern

Citations in the corpus

• Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss (2015, background): “net compared ranibizumab and concurrent photocoagulation against triamcinolone with photocoagulation in patients with DME, and found that ranibizumab achieved better visual outcome at 1-year follow-up than triamcinolone, except in a subset of patients with pseudophakic eyes [130].”
• Inflammation in Diabetic Retinopathy (2011, positive): “Macular edema in diabetic patients can be significantly reduced by intravitreal administration of VEGF antagonists (Elman et al., 2010; Kashani et al., 2010), or steroids (Gillies et al.”